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1268histopathologic, immunofluorescent, and ultrastructural
phenotype and to identify the underlying molecular mechanisms
in this rare genodermatosis.
Methods: Histopathologic, electron microscopy, and
immunofluorescent studies were performed. Whole-exome
sequencing data were interrogated for mutations in desmosomal
and other skin structural genes, followed by Sanger sequencing
of candidate genes in the patient and his parents.
Results: No mutations were identified in DSG1; however, a novel
de novo heterozygous missense c.1757A>C mutation in the
desmoplakin gene (DSP) was identified in the patient, predicting
the amino acid substitution p.His586Pro in the desmoplakin
polypeptide.
Conclusions: SAM syndrome can be caused by mutations in
both DSG1 and DSP. Knowledge of this genetic heterogeneity is
important for both analysis of patients and genetic counseling of
families. This condition and these observations reinforce the
importance of heritable skin barrier defects, in this
case desmosomal proteins, in the pathogenesis of atopic disease.
(J Allergy Clin Immunol 2015;136:1268-76.)
Key words: Atopy, skin barrier, atopic dermatitis, desmosome,
desmoplakin, atopic sensitization, eosinophilic esophagitis
Mendelian skin diseases that include atopic dermatitis (AD) or
AD-like dermatitis, food allergies, or both as part of their
phenotype potentially offer significant insights into disease
pathogenesis. The best examples of insights into AD pathogenesis
from Mendelian disease are Netherton syndrome (Mendelian
Inheritance in Man [MIM] #256500) and ichthyosis vulgaris
(MIM #146700). The discovery of mutations in the serine
protease inhibitor Kazal-type 5 gene (SPINK5) as causative for
Netherton syndrome1 highlighted the role of excessive stratum
corneum protease activity in patients with AD, and identification
of mutations in the filaggrin gene (FLG) in patients with ichthyo-
sis vulgaris2 has been transformative in our understanding of the
importance of the skin barrier in patients with AD and those with
allergic sensitization.3,4 Other rare genodermatoses, such as ‘‘type
B’’ peeling skin syndrome, which is attributed to mutations in the
corneodesmosin gene (CSDN),5 reinforce the importance of stra-
tum corneum cohesion in the pathogenesis of AD.6 In 2013, a new
syndrome designated severe dermatitis, multiple allergies, and
metabolic wasting (SAM) syndrome was attributed to loss-of-
function mutations in the desmosomal plaque protein desmoglein
1 (desmoglein 1 gene [DSG1]).7 Four cases of SAM syndrome
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we report the first case of SAM syndrome (MIM #615508) attrib-
uted to a missense mutation affecting the plakin domain of the
desmoplakin gene (DSP).METHODS
Clinical history
We report the case of a white boy, now aged 6 years, with SAM syndrome.
The patient is the first child of Irish, nonconsanguineous healthy parents. He
was born at 39 weeks and 5 days’ gestation by means of an emergency
cesarean section because of fetal bradycardia after rupture of the membranes.
He weighed 3.18 kg at birth (25th percentile). The perinatal history was
suggestive of a collodion membrane. Erythroderma with ‘‘skin scaling and
peeling’’ was reported to be present from the first weeks of life. He was
referred to our department at 6 months of age. He had marked erythroderma,
ichthyosis, palmoplantar keratoderma (PPK) with nail dystrophy, and diffuse
hypotrichosis. (Fig 1, A, C, and D). Intermittently, especially with
erythrodermic flares, he had a widespread superficial pustulosis (Fig 1, E).
He also had severe and intractable itch. He was on the second percentile for
weight and the fourth percentile for height. He also had macrocephaly, with
his occipitofrontal circumference being greater than the 99th percentile;
global developmental delay; and nystagmus.
In the first 3 years of life, the patient had repeated episodes of systemic
sepsis necessitating hospital admission for intravenous antibiotics and
supportive management. These septic episodes were accompanied by
photophobia, with a flare in ichthyosiform erythroderma and pustulosis and
an exacerbation in itch. The most frequently isolated pathogens causing sepsis
were both the methicillin-sensitive and methicillin-resistant strains of
Staphylococcus aureus. An extensive metabolic, immunologic, and infectious
disease workup did not yield a specific diagnosis. The consensus opinion was
that the source of infection was the patient’s skin. He failed to thrive and had
frequent vomiting, abdominal pain, diarrhea, and food aversion. Several
therapeutic approaches to improve his nutrition failed. A percutaneous
endoscopic gastrostomy tube was sited when he was 10 months of age to
provide essential supplemental feeding.
Neurologic assessment confirmed mild global developmental delay.
Computed tomographic brain scanning demonstrated mild dilatation of the
lateral and third ventricles, with diffuse prominence of sulci over both cerebral
hemispheres. The brain appeared otherwise normal. Ophthalmology
assessment demonstrated keratitis. Binocular visual evoked responses and
electroretinographic results were within normal limits. Despite extensive
assessment, no cause of nystagmus was established. The results of cardiology
workup, including echocardiography, were unremarkable.
Several therapeutic approaches to treat the patient’s skin and systemic
infection were tried with variable success. Potent topical corticosteroids and
corticosteroid and antimicrobial combination therapy yielded minimal
improvement. Topical tacrolimus ointment, with careful monitoring of
tacrolimus blood levels, resulted in moderate improvement. The patient’s
skinwas observed to improvewhen he received antibiotics for systemic sepsis.
Prophylactic anti-staphylococcal antimicrobials had no effect. A trial of
anakinra proved ineffective. Systemic acitretin (0.5 mg/kg/d) had good effect,with a significant improvement in PPK and ichthyosis. Intravenous immuno-
globulin infusions were also effective in reducing the frequency of septic
episodes. The combined beneficial effects of acitretin, intravenous immuno-
globulin, and percutaneous endoscopic gastrostomy feeding have allowed
improvement in the patient’s dermatitis, growth and weight gain, and
development (Fig 1, B). His hair started to grow when he was 6 years old
and is a wooly hair phenotype. Also, he has had ongoing poor periodontal
health, with marked hypodontia.
The patient was atopic, with multiple food allergies. Blood investigations
were consistent with atopy, with persistent eosinophilia (0.4-0.5 3 109/L) and
increased IgE levels (611 kU/L). Analysis of specific IgEs confirmed sensitiza-
tion to egg, peanut, and wheat, despite having no oral exposure to these foods.Histopathologic findings
Skin biopsies performed when the patient was 3 and 16 months of age
showed similar findings (Fig 2,A). Therewas hyperkeratosis and parakeratosis
overlying an acanthotic epidermis. The granular layer was absent, and there
was no evidence of acantholysis. A superficial dermal inflammatory infiltrate
composed of lymphocytes, admixed neutrophils, and histiocytes was present
(Fig 2, B). A skin biopsy of the pustular eruption performed when the patient
was 26months of age showed a florid pustular dermatosis superimposed on the
previously reported histologic findings (Fig 2, B). The pustule was
intraepidermal and restricted to the stratum corneum. Hair microscopy was
noncontributory, and notably, there was no trichorrhexis invaginata.
Esophageal biopsies were done when the patient was 10 and 16 months old.
They showed separation, detachment, and acantholytic sloughing of the
superficial squamous epithelial cells in the absence of any significant
inflammatory process or spongiosis (Fig 2, C).Molecular genetics analysis
Whole-exome sequencing (WES) was performed in the proband with the
Agilent SureSelect v4 capture kit (Agilent Technologies, Santa Clara, Calif)
and sequenced on an Illumina HiSeq 2000 (Illumina, San Diego, Calif;
GenePool, Edinburgh, United Kingdom). The resulting 88.7M 100-bp PE
sequencing reads were aligned to the human genome (Ensembl release 68)
with Bowtie2 (version 2.02; 98.8% aligned).9 Read duplicates were removed
with Picard Tools (version 1.79; http://picard.sourceforge.net), and variants
were called by using the UnifiedGenotyper in GATK-lite (version 2.2-8)
according to the GATK best practices.10 The 69,732 called variants were
annotated with the Variant Effect Predictor (version 72),11 and any variants
with the following consequences were filtered out: downstream_gene_variant,
upstream_gene_variant, synonymous_variant, intergenic_variant, and
intron_variant. Filtered data were put in a MySQL database, allowing
querying through a Django interface. The desmoplakin variant p.His586Pro
was confirmed by means of Sanger sequencing with the primers and
conditions previously reported for exon 14 of the DSP gene.12 Array
comparative genome hybridization (aCGH) was carried out with the Cytoscan
750K high-density oligo array (Affymetrix UK, High Wycombe, United
Kingdom), according to the manufacturer’s recommended conditions
(analysis performed under contract by the South East Scotland Cytogenetics
Laboratory, Western General Hospital, Edinburgh, United Kingdom).Ultrastructure
Skin biopsy specimens were prefixed in half-strength Karnovsky fixative,
followed by postfixation in reduced 1% OsO4 containing 1.5% potassium
ferrocyanide. After embedding in an Epon epoxy resin, ultrathin sections
(600 A) were mounted on Formvar-coated grids, counterstained with uranyl
acetate and lead nitrate, and examined in a Jeol JEM 100 CX electron
microscope (60 kV).Immunohistochemistry of skin biopsy specimens
Four-micrometer paraffin-embedded sections were baked overnight at
608C and deparaffinized with xylene, followed by a gradient of ethanol
FIG 1. Clinical phenotype. A, Generalized erythroderma and ichthyosis when the patient was 6 months of
age. Hypotrichosis and macrocephaly are also evident. B, Improvement in erythrodermic ichthyosis after
treatment with acitretin. C, Plantar keratoderma. D, Erythema, scaling, and diffuse hypotrichosis of the
scalp. E, Pustulosis on the abdomen during an episode of systemic sepsis.
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retrieval was done by heating sections to 958C for 15 minutes in 0.01 mol/L
citrate buffer (pH 6.0). Slides were blocked in 1% BSA and 2% normal goat
serum and incubated for 1 hour at 378C. Primary antibodies were diluted in 1%
BSA and 2% normal goat serum and incubated overnight at 148C. Mouse
mAbs used were as follows: 4B2 (desmoglein 1; diluted 1:100)13 and 115F
(desmoplakin, a gift fromDavid Garrod; diluted 1:100). Polyclonal antibodies
used were as follows: keratin 10 (a gift from Julie Segre; diluted 1:2000) and
1407 (plakoglobin, diluted 1:2000). Secondary staining was done with Alexa
Fluor–conjugated antibodies to mouse, rabbit, or chicken (Life Technologies,
Grand Island, NY) diluted 1:300 in 1%BSA and 2% normal goat serum for 30
minutes at 378C. All washes were done with PBS. Coverslips were mounted
with polyvinyl alcohol for microscopic analysis by using a DMR Leica
microscope (340 NA 1.0 Plan-Fluotar Plan-Apochromat objective) and a
charge-coupled device camera (Orca 100 model CA7 42-95; Hamamatsu
Photonics, Hamamatsu City, Japan). 49,6-Diamidino-2-phenylindole was
added during the secondary antibody incubation at a final concentration of
2 mg/mL.RESULTS
Molecular genetics
Initial mutation screening of the proband’s genomic DNA
isolated from peripheral blood was unremarkable. This included
Sanger sequencing of the entire coding sequences of SPINK5 and
ADAM metallopeptidase domain 17 (ADAM17), as well as 8
genes known to cause autosomal recessive congenital ichthyosis
(NIPAL4, CYP4F22, ALOXE3, ALOXE12B, TGM1, PNPLA1,
ABCA12, CERS3, FATP4, and ABHD5) and pustular psoriasis
(CARD14 and IL36RN). Results of DNA repair studies were
entirely normal. The patient had a normal male karyotype, and
aCGH showed no major deletions or duplications.
The proband’s DNA was then subjected to WES. Given the
known association of DSG1 mutations in prior cases of SAM
syndrome, we screened WES variant data for mutations inDSG1 and related desmosomal genes. Repetitive analysis was
initially focused on the DSG1 gene, which was previously
reported to be causative in patients with SAM syndrome. No
potentially pathogenic variants were identified in the DSG1
gene, and therefore genes encoding other desmosomal proteins
were examined. Only nonpathogenic single nucleotide
polymorphisms (SNPs) that have been found in healthy
populations by the 1000 Genomes Project were identified in the
desmosomal protein genes listed in Table I, with the exception
of the novel point mutation c.1757A>C in DSP (encoding
desmoplakin) predicting the amino acid substitution mutation
p.His586Pro in the desmoplakin polypeptide.
The mutation was confirmed by means of Sanger sequencing
(Fig 3, A and B) and excluded from 100 unrelated, ethnically
matched healthy control subjects (200 alleles) by using Sanger
sequencing. The mutation was not detected in the proband’s
parents, indicating that it represents a de novo change. This
mutation lies within the plakin domain of desmoplakin, which
is shared by other members of the plakin protein family (Fig 3,
C). The crystal structure of residues 175 to 630 of desmoplakin
was described by Choi and Weis.14 Histidine 586 is located in
an a-helix within spectrin repeat 6, a structure that is conserved
in bullous pemphigoid antigen 1 and plectin.14 Histidine is a
hydrophilic charged amino acid, whereas proline is a hydrophobic
residue, and therefore this is a nonconservative amino acid
substitution. More importantly, proline introduces a strong turn
structure within polypeptide chains, and therefore this variant is
strongly predicted to completely disrupt the conserved a-helix
within desmoplakin’s spectrin repeat 6.15,16
As an incidental finding, both the proband and his father were
heterozygous for a c.6208G>A missense SNP in DSP, predicting
the protein change p.Asp2070Asn (Table I). This SNP
(rs41302885) was absent in maternal DNA. SNP rs41302885
has been found at a low frequency in healthy populations, with
FIG 2. Histopathology. A, Skin showing irregular psoriasiform hyperplasia,
hyperkeratosis andparakeratosis, andamildsuperficial dermal inflammatory
infiltrate. B, Skin showing a florid subcorneal pustular dermatosis superim-
posed on background changes similar to those in Fig 2, A, with irregular
hyperplasia and marked hyperkeratosis and parakeratosis. C, Esophageal
squamous mucosa showing separation and detachment of superficial squa-
mous epithelial cells in the absence of any mucosal inflammatory process.












DSP Desmoplakin p.Asp2070N Het rs41302885 0.0026
p.His586Pro Het None None
DSG1 Desmoglein 1 p.Met11Val Hom rs1426310 0.3626
DSG2 Desmoglein 2 p.Ile293Val Het rs2230234 0.0323
p.Arg773Lys Het rs2278792 0.2400
DSG3 Desmoglein 3 p.Thr912Ala Hom rs1380866 0.0008
DSG4 Desmoglein 4 p.Ile644Leu Hom rs4799570 0.0341
DSC1 Desmocollin 1 p.Met659Thr Het rs28620831 0.0220
p.Cys848Phe Het rs985861 0.0933
DSC2 Desmocollin 2 p.Ile776Val Het rs1893963 0.1965
DSC3 Desmocollin 3 None
JUP Plakoglobin p.Arg142His Het rs41283425 0.0240
p.Met697Leu Hom rs1126821 0.4167
PKP1 Plakophilin 1 None
PKP2 Plakophilin 2 None
PKP3 Plakophilin 3 p.Gly95Arg Het rs11246148 0.3608
PKP4 Plakophilin 4 None
CSDN Corneodesmosin None
EVPL Envoplakin p.Gln433Arg Het rs2071192 0.3241
EVPLL Envoplakin-like p.Ser4Asn Het rs570145 0.4766
PPL Periplakin p.Arg819Ser Hom rs2734742 0.0617
p.Ala1007Val Het rs2075639 0.1194
Het, Heterozygous; Hom, homozygous.
Variables in boldface are disease causing.
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www.ncbi.nlm.nih.gov/SNP/) and 0.0033 (ExomeVariant Server;
http://evs.gs.washington.edu). Therefore this variant, like thoseseen in other desmosomal genes (Table I), is predicted to be a
nonpathogenic polymorphism.
High-density aCGH was performed to exclude the presence of
a second compound heterozygous genomic mutation that
might be missed by both WES and targeted PCR-based
sequencing, such as deletion or duplication of 1 or more exons.
The Affymetrix 750K array used had full probe coverage for all
exons of the DSP and DSG1 genes. No copy number
changes were observed for either gene by using high-density
aCGH. Consistent with this result, the coverage of WES
sequence reads across the DSP gene was not significantly
different from that of matched control samples (data not shown).
Thus all molecular genetics data are consistent with the de novo
missense mutation p.His586Pro in DSP being the causative
genetic lesion.Ultrastructural analysis
In normal human epidermis keratin filaments make looping
attachments with the inner plaques of desmosomes.17 Electron
microscopy of the patient’s skin (Fig 4) showed a striking
disassociation between keratin filament bundles (asterisks in the
control tissue image) and desmosomes in the spinous layer of
the epidermis, where desmosomes are most clearly visualized
(Fig 4, A and B). The desmosomal inner plaques were much
less electron dense and appeared poorly formed compared with
desmosomes observed in normal control skin (Fig 4, C and D).
The stratum corneum also displayed striking structural
abnormalities (Fig 5), including marked attenuation of cornified
envelopes (Fig 5, J, double arrows), a virtual absence of
FIG 3. Molecular genetics. A, Pedigree of the family in this study. The arrow indicates the proband.
B, Sequence of the DSP exon 14 spanning codons 584 to 588. Both parents are wild-type for this region,
and the proband has the heterozygous missense mutation c.1757A>C (indicated by the arrow), predicting
the amino acid substitution p.His586Pro at the protein level. C, Primary structure of desmoplakin. Amino
acid boundaries of the 3 major domains of the protein are indicated. The p.His586Pro mutation lies within
the plakin domain in the N-terminal head of desmoplakin.
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maturation (Fig 5, C) and organization of secreted lamellar
body contents (Fig 5, B, and E-G).Immunohistochemistry
Immunofluorescence analysis revealed aberrant desmoplakin
staining, appearing as large accumulations or aggregates (Fig 6, A
and B). Striking reductions in both desmoglein 1 and keratin 10
staining were observed (Fig 6, E-H). What DSG1 remainedappeared in aggregates. Plakoglobin distribution appeared less
perturbed, with largely plasma membrane–associated staining
punctuated by fluorescence-bright regions that colocalized in
some cases with desmoplakin aggregates (Fig 6, C and D).DISCUSSION
Intercellular junction complexes are a diverse group of
organelles that function to provide adherence and communica-
tion between individual cells, as well as contributing to the
FIG 4. Ultrastructural abnormalities. A, Abundant keratin filaments (asterisks) anchored to desmosomes
(arrows) in the cytoplasm of a spinous cell in normal human epidermis. B, Note the scarcity of keratin
filaments at the same level in the proband. C, Common desmosomal structure with normal inner dense
plaque (arrowheads) in a human control sample. D, In contrast, a poorly formed inner dense plaque lacking
evidence of keratin filament attachment was observed in the proband.
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desmosomes, adherens junctions, tight junctions, and gap
junctions.18 Desmosomes are intercellular attachment and
anchoring sites for the intermediate filament cytoskeleton.19
Electron microscopic studies have characterized their ultra-
structure as containing the intermediate filament-associated in-
ner plaque, an electron-dense outer plaque, the plasma
membrane, and the electron-dense midline in the extracellular
domain.18
Desmosomes are composed of several transmembrane and
intracellular molecules. The transmembrane proteins facilitating
intercellular adhesion are desmosomal cadherins, desmogleins,
and desmocollins.17 Intracellular domains are attached to the
intermediate filaments through a range of linker molecules,
including desmoplakin, plakoglobin, and plakophilins.17
Desmosomal structures are widely expressed in epithelia,
including the intestinal mucosa, gall bladder, uterus and oviduct,
liver, pancreas, stomach, salivary and thyroid glands, and
epithelial cells of the nephron, but they are most abundant in
tissues that experience mechanical stress, such as the skin and
myocardium.18 Not only do desmosomes provide resistance to the
strong mechanical forces applied to skin and cardiac muscle and
therefore contribute to tissue cohesiveness, they also have a role in
cell signaling and skin barrier functionality.17,19 These important
functions explain, in part, the diverse range of disease phenotypes
observed in patients with desmosomal diseases. Genetic
abnormalities in desmosomal components result in a variety of
skin and cardiac diseases.Desmoplakin is an obligate component of functional desmo-
somes and is highly expressed in the heart, epidermis,18,19 and
hair follicles.20 Desmoplakin associates with intermediate
filaments through its C-terminus and interacts with plakophilins
and plakoglobin through its N-terminus to target the
desmoplakin-keratin complex to the desmosomal inner
plaque.21,22 Desmoplakin haploinsufficiency has been reported
to cause autosomal dominant type II striate PPKwithout any other
skin, hair, or extracutaneous features.23 This clinical phenotype
suggests that a 50% expression level of desmoplakin is sufficient
for epidermal functioning in most body sites but not for the palms
and soles, which are subject to considerable mechanical stress.17
Recessive mutations in desmoplakin result in severe phenotypes.
Carvajal syndrome is characterized by striate PPK, woolly hair,
and left ventricular cardiomyopathy.24 Skin fragility/woolly
hair syndrome is also caused by recessive mutations in DSP.
Reported cases included compound heterozygosity for a
nonsense/missense combination of mutations. The clinical
phenotype described in the reports was a focal and diffuse PPK,
hyperkeratotic plaques on the trunk and limbs, and varying
degrees of alopecia but no apparent cardiomyopathy. Heterozy-
gous carriers of these mutations displayed no phenotypic abnor-
malities.12 Lethal acantholytic epidermolysis bullosa has been
reported in a neonate presenting as complete alopecia, neonatal
teeth, nail loss, extensive skin erosion, and neonatal death. The in-
fant had compound heterozygosity for a recessive nonsense and
frameshiftDSPmutation, resulting in deletion of the intermediate
filament-binding sites in the desmoplakin tail domain.25
FIG 5. Stratum corneum (SC) ultrastructural abnormalities.A,Mature lamellar bilayers (arrows) and normal
postsecretory lipid processing in the upper portion of the stratum granulosum (SG)–SC interface in normal
human skin. B and C, In addition to areas of processed lamellar bilayer arrays (arrows), the patient sample
shows abnormal lamellar bilayer organization with disruption by nonlamellar domains (Fig 5, B, asterisks),
delayed lipid processing, and incompletely processed lamellar material (Fig 5, C, arrows and asterisks,
respectively). D, Normal lamellar body secretion with homogenous extracellular bilayers in a healthy
human. E and F, Inhomogenous lamellar body secretion with foci of vesicular contents at the SG-SC
interface and premature secretion in the stratum spinosum (SS) in the patient. G, Predominantly abnormal,
ellipsis-shaped lamellar bodies with aberrant internal structures in the patient. H-J, Non–membrane-bound
droplets throughout the SC, containing electron-dense material, possibly lipids (Fig 5, H). In contrast to the
normal regular cornified envelope (double arrows) and corneocyte lipid envelope (Fig 5, I, arrowhead), note
the thinning of the cornified envelope (double arrows) and absence of the corneocyte lipid envelop in the
patient (Fig 5, J).
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DSPmutation. The recently reported families with SAM syndrome
had biallelic loss-of-function mutations in DSG1.7,8 Desmoglein 1
is a member of the desmosomal cadherins and strongly expressedin the granular and spinous layers of the epidermis18,19 and hair fol-
licles.20 Heterozygous mutations inDSG1 cause type I striate PPK.
Homozygous DSG1 mutations were reported to cause the severe
phenotype of SAM syndrome.7 The first reported cases were
FIG 6. Immunostaining. Paraffin-embedded sections of control biopsy
material from patients and control subjects were stained for key desmo-
some components and interacting epidermal proteins (control epidermis:
A, C, E, andG, left panels; proband: B, D, F, and H, right panels). Fig 6, A and
B, Staining for desmoplakin (DSP; green). Note the reduction in staining in
the proband’s skin plus the accumulation of desmoplakin in the cytoplasm.
Fig 6, C and D, Plakoglobin staining (PG; red) is weaker in the patient’s skin
and appears less intense at the cell borders. Fig 6, E and F, Desmoglein 1
expression (DSG1; green) is drastically reduced in the patient’s epidermis.
Fig 6, G and H, Staining for keratin 10 (K10), a major component of the
intermediate filament cytoskeleton in suprabasal keratinocytes, which
was greatly reduced in the proband. Nuclei were visualized with 49,6-
diamidino-2-phenylindole. The dashed line in each image indicates the
location of the dermal-epidermal junction. Calibration bar 5 20 mm.
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described phenotype was congenital erythroderma; skin erosions
and scaling; yellowish papules and plaques at the periphery of
the palms, along the fingers, and over weight-bearing areas of the
feet; and hypotrichosis. From early infancy, they had markedly
increased IgE levels, severe food allergies, and recurrent infections
with severe metabolic wasting.7 Minor cardiac developmental de-
fects were noted in 2 patients, which is in keeping with the associ-
ation between desmosomal diseases and cardiac conditions.7 Twoof the patients also had esophageal involvement, which was similar
to our patient.7 The fourth reported case, the only child of healthy
unrelated parents, had a milder phenotype with PPK, dermatitis,
and multiple allergies but had normal hair and was otherwise
well.8 Samuelov et al7 demonstrated that DSG1 deficiency was
associated with increased expression of genes encoding the
allergy-related cytokines thymic stromal lymphopoietin, IL-5,
and TNF. It is notable that our patient and other patients with
SAM syndrome had esophageal involvement; our patient had
separation and detachment of the esophageal superficial
squamous cells, and another patient with SAM syndrome had
typical eosinophilic esophagitis.7 Similar to SAM syndrome,
eosinophilic esophagitis is characterized by allergic inflammation
of the esophageal mucosa, immune sensitization to foods, and
impaired esophageal barrier function.26 Recent data have
suggested a functional role for DSG1 and its dysregulation in the
pathophysiology of eosinophilic esophagitis. Furthermore, the
loss of DSG1 expression might potentiate allergic inflammation
through induction of proinflammatory mediators.26
Our patient showed amarked reduction in desmoglein 1 protein
expression, as shown by immunohistochemical staining of the
skin (Fig 6), despite not having a DSG1 mutation. This
reduction in expression might be due, at least in part, to disruption
of stable complexes comprising both DSP and DSG1. The
primary structure of desmoplakin has 3 distinct regions: the
1056-amino-acid N-terminal domain, an 890-residue central
coiled-coil domain, and a 925-residue C-terminal intermediate
filament binding domain (Fig 3, C).14 Yeast two-hybrid assays
and coimmunoprecipitation experiments showed that
desmoplakin’s N-terminal 584-amino-acid region is necessary
and sufficient to target desmoplakin to the inner desmosomal
plaque through its association with armadillo proteins.14,21 It is
likely that replacement of histidine with proline in close
proximity to this region disrupts protein conformation and
possibly armadillo protein binding, leading to defects in DSP
localization and function. More recently, the microtubule plus
tip protein end-binding protein 1 was identified as a binding
partner for this same region of desmoplakin.27 In addition, the
observed loss of DSG1 that occurs secondary to desmoplakin
defects might be a causative factor in decreasing keratin
expression because DSG1 suppresses the extracellular signal–
regulated kinase signaling required to promote differentiation,
including expression of genes important for barrier
formation.28,29 ThusDSG1 not only maintains adhesion in the up-
per epidermis but also instructs an early epidermal differentiation
program on stratification.29 The attenuation of differentiation
might also lead to loss of expression of other epidermal proteins,
therefore further exacerbating the barrier defect. Because DSG1
expression or localization is affected in all cases of SAM
syndrome, it is unclear whether it is the loss of DSG1 or DSP at
intercellular junctions that might be causative in the disease.
Although FLG mutations are the most significant mutations
associated with AD, many other genes involved in skin barrier
function have been implicated, including SNPs in the SPINK5
gene.30,31 Homozygous or compound heterozygous loss-of-
function mutations in the SPINK5 gene result in the autosomal
recessive disorder Netherton syndrome, with severe AD and
allergy.1 Furthermore, proteomic profiling of skin from patients
with AD has found that multiple other proteins related to the skin
barrier were expressed at significantly lower levels in lesional
compared with nonlesional sites of patients with AD. These
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mocollin 1, and transglutaminase 3.30 Nonlesional AD skin might
also partially share the lesional skin phenotype. It has been shown
that nonlesional skin has reduced expression of filaggrin and
filaggrin-like proteins,32 aswell as increased expression of immune
genes.33
The pathomechanisms of AD are complex and include
interplay between epidermal structural abnormalities and
immune dysregulation. However, there are several lines of
evidence supporting the role of an aberrant skin barrier in the
development of atopic diseases and allergy. The compromised
skin barrier might allow enhanced allergen exposure to the
cutaneous immune system, enhanced TH2 responses, and
development of allergies. Alternatively, or in addition, the
structural protein-deficient epithelium might be proinflammatory
and primed for the development of allergy.34
We report a fifth case of SAM syndrome and the first case
caused by desmoplakin mutations. SAM syndrome substantiates
the role of heritable skin barrier defects, particularly in
desmosomal proteins, in the pathogenesis of atopic disease. The
pathomechanisms of SAM syndrome require further investigation
and might provide valuable insights into the development of
atopic diseases.
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Clinical implications: Three families with SAM syndrome have
been reported, all with mutations in DSG1. We report a fifth
case, the first linked to a DSP mutation. In patients with SAM
syndrome,mutations inDSG1,DSP, and other desmosomal pro-
teins should be considered.REFERENCES
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